Pharmaceutical Associates Inc, a US-based company that manufactures and markets generic liquid pharmaceuticals, announced on Wednesday, June 16, that it has named Dr. Suketu Sanghvi as its new chief scientific officer.
In the new role, Dr. Sanghvi will head PAI's Research and Development efforts that are focused on oral liquid and sterile injectable products.
Dr. Sanghvi has served as chief scientific officer at Scienture Inc. He was managing the R&D portfolio for Endo Pharmaceuticals and Par Pharmaceutical. He has served in senior scientific roles at Novel Laboratories and Forest Laboratories.
Dr. Sanghvi holds a PhD in Pharmacy with a focus in drug formulation and pharmaceutics from the University of Toronto.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling